IQVIA Holdings Inc. logo IQV - IQVIA Holdings Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 35
HOLD 7
SELL 1
STRONG
SELL 0
| PRICE TARGET: $219.44 DETAILS
HIGH: $250.00
LOW: $185.00
MEDIAN: $215.00
CONSENSUS: $219.44
UPSIDE: 30.80%

Stock News

StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising

StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising

TORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compliant engagement with healthcare audiences. IQVIA Digital's integrated solutions enable marketers to quickly transform data-driven insights into meaningful, privacy-conscious activation across the healthcare ecosystem.Through this collaboration, StackAdapt's programmatic advertising capabilities are n.

Jun 18, 2026 06:17 AM • businesswire.com
Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain

Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies. The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley and IQVIA in May 2026. The sessi.

Jun 15, 2026 05:00 AM • businesswire.com
The Broyhill Q1 2026 Portfolio Strategy And Positioning

The Broyhill Q1 2026 Portfolio Strategy And Positioning

Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.

May 14, 2026 10:55 PM • seekingalpha.com

Price Targets